SAN FRANCISCO, Nov. 13 /PRNewswire-FirstCall/ -- Osteologix, Inc. announced today that it has appointed Jeremy Curnock Cook to its board of directors, effective November 9, 2006. Mr. Curnock Cook is currently the Executive Chairman of Bioscience Managers Limited, a corporate and investment advisory company headquartered in London, England.
“Jeremy has a deep understanding of the biotechnology and pharmaceutical industries, and a tremendous amount of experience investing in public companies in these fields. I am very pleased to announce his appointment to our board of directors,” stated Charles J. Casamento, CEO and President. “His experience in both the United States and abroad should prove valuable to us as we advance NB S101, our investigational drug for the treatment of osteoporosis, through clinical development.”
“I am delighted to join the board of Osteologix,” said Mr. Curnock Cook. “I am very excited about the tremendous potential of the company’s investigational drug for treating osteoporosis. Osteologix’s lead product is close to entering phase II clinical trials, addresses a very large market and has many promising attributes.”
Mr. Curnock Cook founded the International Biochemicals Group in 1975, which was sold to Royal Dutch Shell in 1985; he continued to serve as Managing Director until 1987. From 1987 to 2000, he was a Director of Rothschild Asset Management Limited and was responsible for the Rothschild Bioscience Unit. Mr. Curnock Cook is Chairman of the Board of Targeted Genetics Inc., in Seattle and Inflazyme Pharmaceuticals Ltd. in Vancouver. Mr. Curnock Cook is also a member of the board of directors of Sirna Therapeutics Inc. as well as other companies in the United Kingdom, Canada and Australia.
About Osteologix
Osteologix develops proprietary therapeutics for the treatment of important unmet medical needs in bone disease and women’s health. The Company’s lead product, NB S101, is entering phase II clinical trials for the treatment of osteoporosis. Based on the Company’s own data as well as data from phase III clinical trials conducted on another salt of strontium that is approved for sale in Europe, Osteologix believes that NB S101 increases new bone formation and decreases bone resorption. Osteologix further believes that NB S101 will provide patients with greater convenience and fewer side effects than drugs currently approved for osteoporosis in the United States, Europe and elsewhere, thereby addressing the need for an osteoporosis drug with higher compliance rates and better long term efficacy. The Company is not aware of any osteoporosis drug currently approved for sale in the United States that simultaneously increases bone formation and decreases bone resorption. Osteologix is committed to creating value by building a world- class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Osteologix can be obtained on the Company’s website, www.osteologix.com.
FORWARD-LOOKING STATEMENTS:
Certain of the statements set forth in this press release constitute “Forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. All such forward looking statements involve risks and uncertainties, including, but not limited to: statements regarding Osteologix’s research and development programs; proposed marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; and the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with pharmaceutical companies. There can be no assurance that such forward-looking statements will prove to be accurate and Osteologix undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.
Osteologix, Inc. 425 Market Street, Suite 2230 San Francisco, CA 94105 Charles J. Casamento Matthew M. Loar Chief Executive Officer and President Chief Financial Officer 415-955-2726 415-955-2720
Osteologix, Inc.
CONTACT: Charles J. Casamento, Chief Executive Officer and President,+1-415-955-2726, or Matthew M. Loar, Chief Financial Officer,+1-415-955-2720, both of Osteologix, Inc.
Web site: http://www.osteologix.com/
